$71 million in funding would extend Nanobiotix cash visibility into early 2028 Transaction enables Nanobiotix development beyond key milestones in head and neck cancer and lung cancer Financing ...
Pratteln, Switzerland, November 5, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the closing of a USD 13 million royalty monetization agreement, first announced in September 2025, to support ...
CAMBRIDGE, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (EDIT), a clinical-stage gene editing company, today announced the sale of certain future license fees and other payments owed ...
NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to ...
$150 million secured at closing extends cash runway into early 2027 REGENXBIO retains additional potential non-dilutive funding opportunities, including monetization of Priority Review Voucher (PRV) ...
Under the terms of the agreement, Fluor will convert its remaining Class B units of NuScale Power, LLC (the “Class B units”) into shares of Class A common stock of NuScale (the “Class A common stock”) ...
Renewed Partnership Supports WINDTRE's Commitment to Customer-Centric, Transparent and Differentiated Mobile Experiences FOSTER CITY, CA / ACCESS Newswire / October 21, 2025 / MATRIXX Software, a ...
Fluor Corporation (NYSE: FLR) (“Fluor”) and NuScale Power Corporation (NYSE: SMR) (“NuScale”) today announced that they have reached an agreement regarding the conversion and monetization of Fluor’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback